^
Association details:
| Biomarker: | CDKN1A overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) + AC1Q3QWB (HOTAIR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
COMPOUND AC1Q3QWB UPREGULATES CDKN1A AND SOX17 VIA INTERRUPTING THE HOTAIR-EZH2 INTERACTION AND ENHANCES THE EFFICACY OF TAZEMETOSTAT IN ENDOMETRIAL CANCER
Published date:
10/18/2023
Excerpt:
AQB has demonstrated a promising inhibitory effect on EC cells. When combined with TAZ, the expression of CDKN1A and SOX17 was significantly upregulated, resulting in more potent anti-tumor effects. This combination therapy could provide a novel strategy for treating EC.
